We recently published a list of 10 Best Growth Stocks to Buy According to Billionaires. In this article, we are going to take ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

ASND thrives amid market volatility, with Yorvipath's strong potential & strategic focus on rare diseases. Click here to find ...

The China-based biotech was formed in 2018 by Ascendis Pharma and an investor syndicate led by Vivo Capital. The biotech is designed to develop and commercialize Ascendis’ endocrinology ...

Data demonstrated multiple clinical benefits beyond linear growth— NDA supported by data from three randomized, double-blind, ...

Ascendis Pharma A/S (ASND) shares rallied 10.4% in the last trading session to close at $168.84. This move can be attributable to notable volume with a higher number of shares being traded than in ...

distributors and service providers for Ascendis’ products and product candidates; unforeseen safety or efficacy results in Ascendis’ development programs or on-market products; unforeseen ...

COPENHAGEN, Denmark, March 31, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has submitted its New Drug Application (NDA) to the U.S. Food & Drug ...